What it is
DSIP stands for delta sleep-inducing peptide. A peptide is a short chain of amino acids, the building blocks of proteins. DSIP is nine amino acids long. Its international drug name is emideltide.
More on what it is and where it came from
It was named for what it did in the first rabbit experiments: it increased "delta" waves, the slow brain waves seen in deep sleep. The name has stuck, although later studies in animals and people did not agree on whether it promotes sleep.
The DSIP sold today is made synthetically. It is supplied either as the plain peptide or as an acetate salt, and the FDA notes these two forms behave differently in solution.
Guido Schoenenberger and Marcel Monnier in Basel, Switzerland, isolated it in the 1970s from the blood of rabbits kept asleep by electrical stimulation of the brain, and published its sequence in 1977. Small clinical studies followed in Switzerland and elsewhere through the 1980s. Development as a medicine did not continue.
How it is thought to work
Nobody knows how DSIP works, or whether it has a natural job in the body at all. Unlike most hormones and signalling peptides, no gene that codes for it and no receptor that it acts on has been found.
More on how it works
In animal experiments its effects on sleep were blocked by naloxone, a drug that blocks opioid signalling. Laboratory studies described in the FDA review suggest it does not attach to opioid receptors itself but may prompt the release of the body's own opioid-like substances. This is a hypothesis from animal and laboratory work, not an established mechanism in people.
It is broken down in the blood within minutes, which adds to the puzzle of how a single injection could have lasting effects.
What is established in people
Very little is established in people. The human studies date from 1981 to 1992, plus one in 2009, and all gave DSIP into a vein. The early positive insomnia reports had no placebo group. The two properly controlled insomnia trials, in 6 and 16 people, found weak or no benefit. The largest study, 107 patients in withdrawal, had no comparison group. No trial has tested the injection under the skin that is sold today.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2009
Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
DSIP raised heart rate, reduced delta brain-wave activity and lightened the measured depth of anaesthesia.
Full finding, who was studied, and limits
Who: Twenty-four women having surgery under general anaesthesia: twelve given DSIP and twelve given saline alongside the anaesthetic.
DSIP raised heart rate, reduced delta brain-wave activity and lightened the measured depth of anaesthesia. That is the opposite of what the name suggests.
Read with care: A small study in anaesthetised patients, not natural sleep. It is the most recent human study found.
European journal of anaesthesiology · pubmed.ncbi.nlm.nih.gov
- Human trial1994
Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep
Natural DSIP-like material in the blood was lower during deep sleep and dream sleep than when awake.
Full finding, who was studied, and limits
Who: Twelve healthy volunteers. Blood was sampled every 30 minutes for 24 hours while sleep was recorded. Nobody was given DSIP.
Natural DSIP-like material in the blood was lower during deep sleep and dream sleep than when awake. It peaked in mid-afternoon and was lowest around 1 a.m., tracking body temperature.
Read with care: An observational study of twelve people measuring a blood signal. It runs against the idea that DSIP is the body's sleep hormone, but it cannot settle the question.
The Journal of clinical endocrinology and metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Sleep efficiency was a little higher and sleep onset a little quicker with DSIP, but the authors called the effects weak and said they could partly be due to a chance change in the placebo group.
Full finding, who was studied, and limits
Who: Sixteen adults with long-standing insomnia in a double-blind, matched-pairs, placebo-controlled trial over five nights in a sleep laboratory.
Sleep efficiency was a little higher and sleep onset a little quicker with DSIP, but the authors called the effects weak and said they could partly be due to a chance change in the placebo group. Nothing else changed, including how people rated their own sleep. They concluded short-term treatment was not likely to be of major benefit.
Read with care: Sixteen people. This is the largest controlled trial of DSIP that was found.
- Human trial1987
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
Sleep measures improved over the week: people fell asleep sooner, were awake less during the night and slept longer.
Full finding, who was studied, and limits
Who: Fourteen middle-aged adults with long-standing insomnia, treated for seven nights.
Sleep measures improved over the week: people fell asleep sooner, were awake less during the night and slept longer.
Read with care: The FDA's 2026 review points out that although the paper was described as placebo-controlled, there was no placebo group; the comparison was with a separate matched group. Without a placebo, improvement cannot be credited to the peptide.
- Human trial1987
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Reductions in awakenings and time awake were not significant against either baseline or placebo.
Full finding, who was studied, and limits
Who: Six adults with severe long-standing insomnia in a randomised, double-blind, placebo-controlled crossover trial.
Reductions in awakenings and time awake were not significant against either baseline or placebo. The authors judged the improvement to be of little clinical significance.
Read with care: Only six people, but it is one of the two properly controlled trials, and it was essentially negative.
International journal of clinical pharmacology research · pubmed.ncbi.nlm.nih.gov
- Human trial1984
DSIP in the treatment of withdrawal syndromes from alcohol and opiates
The authors reported that withdrawal symptoms disappeared or improved markedly in most patients.
Full finding, who was studied, and limits
Who: 107 inpatients withdrawing from alcohol (47) or opiates (60) at a university psychiatric hospital in Geneva. Open-label, with no comparison group.
The authors reported that withdrawal symptoms disappeared or improved markedly in most patients. Anxiety was slower to settle, and anxiety with marked insomnia returned within one to three days of stopping in many patients.
Read with care: No control group and no blinding, so the result cannot show the peptide caused the improvement. A share of patients could not be evaluated. A 1998 open-label study in seven people with opioid dependence, described in the FDA review, had only two complete the course.
- Human trial1981
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
This was the first study in people.
Full finding, who was studied, and limits
Who: Six healthy volunteers in a double-blind crossover study, given DSIP or placebo into a vein in the morning.
This was the first study in people. Total sleep over the following two hours or so was longer after DSIP than after placebo, and no side effects were observed.
Read with care: Six people, one occasion each, by infusion into a vein.
International journal of clinical pharmacology, therapy, and toxicology · pubmed.ncbi.nlm.nih.gov
- Review2026
FDA briefing document on emideltide (DSIP) for the Pharmacy Compounding Advisory Committee
The FDA found that DSIP had been given into a vein to about 209 people across the studies it identified, for between 1 and 15 days.
Full finding, who was studied, and limits
Who: The FDA's own review of the published human and animal evidence, written for its advisory committee meeting of 23 and 24 July 2026.
The FDA found that DSIP had been given into a vein to about 209 people across the studies it identified, for between 1 and 15 days. It found no data at all for injection under the skin, which is how it was proposed to be compounded, and no repeat-dose, reproductive or cancer studies in animals. It proposed not adding DSIP to the list of substances pharmacies may compound from.
Read with care: A regulator's review, not a new study. It is the best single summary of the human evidence.
U.S. Food and Drug Administration, dated 11 May 2026 · fda.gov
- Review2006
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
The authors called DSIP "a still unresolved riddle".
Full finding, who was studied, and limits
Who: A review of about thirty years of DSIP research.
The authors called DSIP "a still unresolved riddle". They wrote that its link to sleep had never been properly characterised, partly because no gene, parent protein or receptor for DSIP had been isolated, and that the sleep hypothesis was poorly documented and weak.
Read with care: A review reflects its authors' reading of the field. No later paper identifying a DSIP gene or receptor was found.
- Animal study1987
The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat
Cats fell asleep sooner and had more total and deep slow-wave sleep, an effect that lasted about seven hours.
Full finding, who was studied, and limits
Who: Ten cats, given DSIP directly into the brain.
Cats fell asleep sooner and had more total and deep slow-wave sleep, an effect that lasted about seven hours.
Read with care: Ten animals, and delivery into the brain. It conflicts with the rat studies, which is typical of the DSIP literature.
- Animal study1980
Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat
No significant increase in sleep or in delta brain-wave activity was found.
Full finding, who was studied, and limits
Who: Rats, given DSIP by injection and directly into the brain.
No significant increase in sleep or in delta brain-wave activity was found. The authors concluded DSIP did not qualify as a specific sleep-promoting substance.
Read with care: A negative result in one species. It is included because it contradicts the name.
- Animal study1977
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide
The peptide was isolated from the blood of sleeping rabbits and its nine-amino-acid sequence was reported.
Full finding, who was studied, and limits
Who: Rabbits (58 including controls), given the peptide directly into the brain in a blinded experiment.
The peptide was isolated from the blood of sleeping rabbits and its nine-amino-acid sequence was reported. In rabbits it increased the slow "delta" brain waves seen in deep sleep; related fragments and analogues did not.
Read with care: Rabbits, and delivery straight into the brain. This is the discovery experiment, not evidence about people.
Safety findings
- In the 107-patient withdrawal study, the FDA's review records no significant side effects in 95 patients, short-lived sweating, headache, nausea or dizziness in 9, and 3 serious events, including low blood pressure at the start of an injection. Source: fda.gov
- There are no long-term human safety data. The longest exposure the FDA found was 15 days. Source: fda.gov
- The FDA found no safety information of any kind for injection under the skin, and no animal studies of repeated dosing, effects on pregnancy, or cancer risk. Source: fda.gov
- The FDA's side-effect database held no reports for DSIP. The FDA treats an absence of reports as a lack of monitoring, not as evidence of safety. Source: fda.gov
2 more safety findings
- Because DSIP appears to act through the body's opioid system, the FDA noted it could in theory have habit-forming properties. This has not been studied. Source: fda.gov
- The FDA says compounded DSIP may carry a risk of unwanted immune reactions for some routes of use, and that its impurities are hard to characterise. Source: fda.gov
Rules and status
Not approved. DSIP is not an FDA-approved medicine and the FDA found it registered as a medicine in no other country it checked.
The full history, with dates
In September 2023 the FDA placed DSIP (under the name emideltide) in Category 2 of its interim compounding policy, the group of nominated substances that may present significant safety risks. The two companies that had nominated it later withdrew, and the FDA page dated 22 April 2026 lists it under "nominated but withdrawn", with the stated reason that it "may pose risk for immunogenicity for certain routes of administration" and that the agency "lacks sufficient information to know whether the drug would cause harm if administered to humans". The FDA's category list updated 14 May 2026 shows it in no category. The FDA reviewed it anyway: its briefing document of 11 May 2026 proposed not adding it to the list pharmacies may compound from, and it was discussed at the advisory committee meeting of 23 and 24 July 2026. On 30 October 2026 the Department of Health and Human Services published a draft, non-binding policy on pharmacy compounding of certain peptides; Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and DSIP is not one of them.
Source: fda.gov (source dated 2026-04-22)
In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027). Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. No other section names DSIP, and the FDA found it registered as a medicine in no country it checked, so S0 applies and it is prohibited at all times. For 2027 WADA added 'peptides' as a named example in S0, and WADA's 2027 explanatory note says that even if a peptide is not specifically named on the List, 'it may still be prohibited'. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| DSIP is the body's natural sleep peptide. | No gene, parent protein or receptor for DSIP has been identified, and in the one study that tracked it, natural DSIP-like levels in the blood were lowest during deep sleep. Source: pubmed.ncbi.nlm.nih.gov |
| It is proven to treat insomnia. | The two properly controlled trials, in 6 and 16 people, found weak or no benefit. The largest controlled trial concluded it was not likely to be of major therapeutic benefit. Source: pubmed.ncbi.nlm.nih.gov |
| It has been used safely for decades. | Human exposure in studies was short, 15 days at most, in about 209 people. There are no long-term data and no safety data at all for injection under the skin. Source: fda.gov |
| It helps with drug and alcohol withdrawal. | This rests on an uncontrolled 1984 study of 107 inpatients and a 1998 study of seven people in which only two completed the course. Neither had a comparison group. Source: pubmed.ncbi.nlm.nih.gov |
| The FDA legalised peptides like this in 2026. | Not DSIP. FDA staff proposed not allowing pharmacies to compound it, and it is not among the six peptides named in the federal draft policy of October 2026. Source: govinfo.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match 848.8 g/mol, the molecular weight of the nine-amino-acid sequence WAGGDASGE.
- Which form it is: the plain peptide (free base) or the acetate salt. The FDA notes the two dissolve very differently, so a report should say which was tested.
- Purity by HPLC, with peptide-related impurities listed rather than a single percentage alone.
- Tests for bacterial toxins (endotoxin) and microbial contamination. The FDA noted these were missing from the certificates supplied by the companies that nominated DSIP for compounding.
- A lot number and test date that match the product, and a named laboratory.
What is not known
- Whether DSIP has any natural role in the body. No gene or receptor has been found.
- What form of DSIP the 1980s trials used. The FDA says most papers do not state whether it was the free base or the acetate.
- The advisory committee's vote in July 2026. Trade press reported that the committee voted against DSIP, but no FDA minutes or vote record were found, so the vote is not stated on this page.
- Whether the federal draft policy has been finalised. Its comment period closed in mid-November 2026 and no later notice was found.
Sources
All 21 sources
- Characterization of a delta-electroencephalogram (-sleep)-inducing peptide (1977). pubmed.ncbi.nlm.nih.gov
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle (2006). pubmed.ncbi.nlm.nih.gov
- Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat (1980). pubmed.ncbi.nlm.nih.gov
- The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat (1987). pubmed.ncbi.nlm.nih.gov
- Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep (1994). pubmed.ncbi.nlm.nih.gov
- Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior (1981). pubmed.ncbi.nlm.nih.gov
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (1987). pubmed.ncbi.nlm.nih.gov
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs (1987). pubmed.ncbi.nlm.nih.gov
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study (1992). pubmed.ncbi.nlm.nih.gov
- DSIP in the treatment of withdrawal syndromes from alcohol and opiates (1984). pubmed.ncbi.nlm.nih.gov
- Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia (2009). pubmed.ncbi.nlm.nih.gov
- FDA briefing document on emideltide (DSIP), dated 11 May 2026. fda.gov
- FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026). fda.gov
- FDA: 503A nominated substances by category, updated 14 May 2026. fda.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement-discretion policy notice. govinfo.gov
- WADA 2027 Prohibited List: summary of major modifications and explanatory notes (S0 and peptides). wada-ama.org
- PubChem: Delta Sleep-Inducing Peptide, CID 68816. pubchem.ncbi.nlm.nih.gov
- UniProt: P01158, delta sleep-inducing peptide (rabbit). uniprot.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.